Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Department of Immunology and Inflammation, Imperial College London, London, UK.Issue Date
2020
Metadata
Show full item recordCitation
Lim KHJ, Gomes F. ESMO20 YO for YO: highlights on oncogene-addicted NSCLC. ESMO Open. 2020;6(1):100026.Journal
ESMO OpenDOI
10.1016/j.esmoop.2020.100026PubMed ID
33399088Additional Links
https://dx.doi.org/10.1016/j.esmoop.2020.100026Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.esmoop.2020.100026
Scopus Count
Collections
Related articles
- ESMO20 YO for YO: highlights on metastatic NSCLC-Keynote 024 update.
- Authors: Mariamidze E, Mezquita L
- Issue date: 2021 Feb
- European Society of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for each patient.
- Authors: Suay G, Aparisi F, Juan-Vidal O
- Issue date: 2024 Jun
- Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?
- Authors: Frega S, Bonanno L, Guarneri V, Conte P, Pasello G
- Issue date: 2018 Aug
- Acquired resistance in oncogene-addicted non-small-cell lung cancer.
- Authors: Sini C, Tuzi A, Rossi G, Russo A, Pezzuto A
- Issue date: 2018 Jun
- Personalized targeted therapy in advanced non-small cell lung cancer.
- Authors: Ma PC
- Issue date: 2012 May